The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease
Authors:
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 8 (2) , 67-77
Abstract
Pyoderma gangrenosum (PG) is an ulcerative neutrophilic dermatosis seen in 1–5% of patients with inflammatory bowel disease (IBD). The pathogenesis of PG remains unclear, but may be related to abnormal T-cell responses and production of tumor necrosis factor (TNF)-α, a powerful proinflammatory cytokine. Although their use is not supported by appropriately controlled trials, corticosteroids and systemic immunosuppressants are the classical cornerstones of treatment of PG, against which they have a nonspecific effect. Successful curative or symptomatic treatment of associated disorders may lead to an improvement in PG. A new era for the management of chronic inflammatory disease began with the advent of biotherapies and particularly anti-TNFα therapy, which allows for a specific intervention in the immune cascade. Anti-TNFα therapy has improved and broadened the therapeutic options for IBD and, therefore, has brought new perspectives to management of the extra-intestinal manifestations of this disorder, including PG. To date, infliximab, etanercept, and adalimumab have been used in the treatment of PG. Published data have demonstrated that infliximab is highly effective in the treatment of PG, whether associated with IBD or not. This treatment is generally well tolerated, even as long-term therapy. However, rare and serious complications have been reported. Although infliximab is a costly drug, its use should be considered for patients with PG and particularly with corticosteroid-refractory PG associated with IBD. Additional comparative long-term studies are needed to determine the long-term efficacy and safety of anti-TNFα therapy and define its role in the management of PG, with or without accompanying IBD.Keywords
This publication has 71 references indexed in Scilit:
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Therapy Insight: pyoderma gangrenosum—old disease, new managementNature Clinical Practice Gastroenterology & Hepatology, 2005
- Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patientsJournal of the American Academy of Dermatology, 2005
- Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanerceptAlimentary Pharmacology & Therapeutics, 2005
- Clinical Management of Pyoderma GangrenosumAmerican Journal of Clinical Dermatology, 2002
- Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1β and tumour necrosis factor-α stimulate its secretion in vitroBritish Journal of Dermatology, 2000
- Pyoderma gangrenosumThe Lancet, 1998
- Treatment of pyoderma gangrenosumJournal of the American Academy of Dermatology, 1996
- Pyoderma gangrenosum: Classification and managementJournal of the American Academy of Dermatology, 1996
- PYODERMA (ECHTHYMA) GANGRENOSUMArchives of Dermatology and Syphilology, 1930